A study proposed carbohydrate-binding agents (CBAs) as novel anti-HIV compounds because they target gp120 glycans, inhibiting infection in primary human monocyte-derived macrophages (MDMs) and effectively preventing MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes. This evidence concerns the gene ITIH4 and infection.